CSF Tap Test Parameters and Short-Term Outcomes in operated and non-operated patients with idiopathic Normal Pressure Hydrocephalus: A Cohort Study

Sagar Poudel[1], Deepa Dash[2], Ajay Garg[3], Ashish Dutt Upadhyay[4], Naveet Wig[1], Roopa Rajan[5], Animesh Das [5], Divya M Radhakrishnan[5], Manjari Tripathi[5], Achal K. Srivastava[5], SS Kale[6], P Sarat Chandra[6], Ashish Suri[6], Pramod K Pal[7], Hrishikesh Kumar[8], Sakoon Saggu[5], Deepti Vibha[5], Rajesh Kumar Singh[5], Jasmine Parihar[5], Ranveer Singh Jadon[1], Ved Prakash Meena[1], Bindu Prakash[1], Arunmozhimaran Elavarasi[5]

1Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
2Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada
3 Department of Biomedical Sciences, Humanitas University, Milan, Italy
4 Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India
5 Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
6 Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India
7 Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, India
8 Movement Disorders Program, Institute of Neurosciences, Kolkata, India

Corresponding Author

Dr Arunmozhimaran Elavarasi

Department of Neurology, All India Institute of Medical Sciences, New Delhi, India

Email: arun_ela@yahoo.com

Word count: 2742

Number of references: 10

Number of figures: 2

Number of tables: 3

Supplementary file: 1

Abstract:

Background

Normal Pressure hydrocephalus (NPH) is treated by insertion of a ventriculoperitoneal shunt. The cerebrospinal fluid (CSF) tap test is widely used to identify candidates for shunt surgery in idiopathic NPH (iNPH). However, its predictive value remains uncertain. This study aimed to compare the CSF tap test responses and 24-week functional outcomes between patients with probable iNPH who underwent surgery and those who did not.

Methods

This Ambispective cohort study included 40 patients with probable iNPH based on Relkin's guidelines from 2019 to 2024. All patients underwent a large volume CSF-TT. They were offered surgery based on the clinico-radiologic profile.

Results

Twenty-four patients with probable iNPH underwent ventriculoperitoneal shunt surgery based on clinico-radiologic profile, irrespective of the CSF tap test response as per Japanese guidelines, and 16 did not for various reasons. No significant differences were found in the baseline or 24-hour post-CSF tap test parameters between the groups. At 24 hours post-tap, there were no significant differences in the changes in gait, cognition, or mRS scores. However, at 24 weeks, 62.5% of operated patients showed at least a 1-point mRS improvement, while only 14.3% in the non-operated group had a similar improvement, indicating the beneficial role of VP shunting in NPH. Interestingly, 46.7% of patients who did not respond to the tap test but underwent surgery still benefited from shunting.

Conclusion

Shunt surgery leads to a favorable short-term functional outcome in patients with probable iNPH compared to patients with a similar profile who did not undergo surgery. However, the CSF tap test alone lacks sufficient discriminatory power to guide surgical decisions in a cohort of patients with clinico-radiological probable iNPH. A negative tap test should not preclude surgery in patients with supportive clinical and imaging features.

Introduction

Normal pressure hydrocephalus is diagnosed based on clinical and radiologic features, as well as ancillary testing, such as the CSF tap test. Imaging features such as disproportionately enlarged subarachnoid space hydrocephalus (DESH) in the right clinical context are termed probable NPH as per the Japanese guidelines, while a diagnosis of definite NPH is made based on the response to shunt surgery.[1] The CSF tap test has been considered an important ancillary test to determine a patient's candidacy for shunt surgery.[2,3] A nationwide survey done among Indian Neurologists showed marked heterogeneity with several respondents referring for surgery only if the CSF-TT was positive.[4] The decision to subject a patient to the CSF tap test is based on clinico-radiologic features such as the triad of gait, cognitive, and urinary symptoms. The SINPHONI2 trial demonstrated that in patients with probable NPH, as defined by the Japanese guidelines, delaying lumbo-peritoneal shunt surgery, regardless of the CSF-TT results, led to poorer outcomes.[1,5] We report the short-term outcomes of ventriculoperitoneal shunt in a cohort of patients who were determined to have probable idiopathic normal pressure hydrocephalus (iNPH) based on a clinico-radiologic profile and compare them with those who were considered for surgery but did not undergo shunting for various reasons. We also compared the response to the CSF tap test between those who underwent surgery and those who did not.

Methods

This was an ambispective cohort study where patients who presented to a tertiary care center in Northern India from 2019 to 2024 with possible NPH according to Relkin guidelines[6] with at least one of the specific triad of symptoms of NPH - gait disturbance, urinary disturbances, or cognitive impairment, were recruited. Patients from 2019 to 2023 were recruited retrospectively by reviewing the patients' charts obtained from the institute's medical records, and patients from 2023 to 2024 were recruited prospectively. The study was approved by the Institutional Review Board. The study was designed and reported according to the STROBE reporting guidelines.

Based on the history, examination, and imaging findings, we excluded patients who were unlikely to have iNPH. (Figure 1) Demography, clinical features, medical treatment, baseline gait, cognitive and urinary parameters were recorded in a structured case record form. Patients underwent baseline and post-CSF-TT evaluations of gait, urinary, and cognitive function using the Boon's gait scale, modified Rankin scale, TUG test, Montreal Cognitive Assessment (MoCA), and the iNPH scale, as per the Institute protocol.[7] Patients who had probable iNPH (Box 1) as per Japanese guidelines[1] were offered a programmable VP shunt irrespective of the results of the CSF-TT. The imaging findings, correlation of cerebrospinal fluid opening pressures with response to the CSF-TT outcomes, and shunt responsiveness in this cohort of patients[7] have been reported in other publications.

Box 1: Diagnostic certainty of iNPH as per Japanese guidelines[1]
Possible iNPH Possible iNPH is diagnosed if the following criteria are met: 1. More than one symptom in the clinical triad: gait disturbance, cognitive impairment, and urinary incontinence 2. The above-mentioned clinical symptoms cannot be completely explained by other neurological or non-neurological diseases. 3. Preceding diseases possibly causing ventricular dilation (including subarachnoid hemorrhage, meningitis, head injury, congenital/developmental hydrocephalus, and aqueductal stenosis) are not obvious.
Probable iNPH Probable idiopathic normal pressure hydrocephalus (iNPH) is diagnosed if a patient exhibits all of the following three features. 1. Meets the requirements for possible iNPH 2. CSF pressure of 200 mmH2O or less and normal CSF content 3. One of the following two investigational features: (a) Neuroimaging features of narrowing of the sulci and subarachnoid space over the high-convexity/ midline surface (DESH) with gait disturbance: small stride, shuffle, instability during walking, and an increase in instability on turning (b) Improvement of symptoms after CSF tap test and/or drainage test
Definite iNPH When objective improvement is seen after shunt surgery

Short-term outcome

The patients were followed up, and outcomes at 24 weeks following surgery were assessed using the modified Rankin scale. In patients who did not undergo surgery, outcome assessment was performed 24 weeks following the CSF-TT. In the retrospective arm, telephonic interviews were conducted to assess the patient or caregiver recall based on the modified Rankin scale at 24 weeks. We defined shunt responsiveness as a reduction of at least 1 point on the mRS at 24 weeks after the Ventriculoperitoneal shunt surgery. For prospectively recruited patients, we also assessed the iNPH score at 24 weeks, and a one-point reduction was considered indicative of shunt responsiveness. The assessments were conducted either in-clinic during follow-up visits or telephonically, as per the patient's preference.

Statistical analysis

Data were collected and managed using REDCap (Research Electronic Data Capture), a secure, web-based application designed to support data capture for research studies. The REDCap platform used in this study was hosted by the All India Institute of Medical Sciences (AIIMS), New Delhi, India. Data were exported and cleaned using Microsoft Excel (Microsoft Corp., Redmond, WA, USA). Descriptive statistics, including frequencies and percentages, were used to describe categorical variables. Mean and standard deviations were used for continuous variables with a normal distribution, while medians and interquartile ranges were used for non-parametric data. For comparisons between groups, an independent samples t-test was used for normally distributed data, and the Mann–Whitney U test was used for non-normally distributed data. Dichotomous variables were compared using the Chi-squared test or Fisher's exact test. All statistical analyses were performed using Stata version 17 (StataCorp, College Station, TX, USA). A p-value of <0.05 was considered statistically significant.

Results

We screened 48 patients: 20 in the retrospective arm (2019-2022) and 28 in the prospective arm. Eight patients were excluded as they were unlikely to have NPH, and 40 patients underwent a CSF-TT. Out of 40 patients considered for a CSF-TT, 24 underwent VP shunt surgery, and 16 did not for various reasons (Figure 1). The median duration to VP shunt after CSF-TT was 22.5 days (IQR 12.5-65). There were no significant differences in demographics, clinical features, or various scores between the groups at baseline; the results are summarized in Table 1 and Supplementary Table 1.

Figure 1: Patients screened and included in the study



Table 1: Baseline features of patients with probable iNPH who underwent the CSF-TT

Parameter	Operated (n=24)	Non-Operated (n=16)	p-value
Age (years), mean± SD	64.1 ± 9.5	64.8 ± 8.2	0.79
Gender (male), n(%)	20 (83.3%)	15 (93.8%)	0.63
Symptom duration (months), median (IQR)	24 (18.5-42)	36(15-48)	0.71
Gait dysfunction, n(%)	24 (100%)	15 (93.8%)	0.4
Cognitive dysfunction, n(%)	22 (91.7%)	15 (93.8%)	>0.99
Urinary Disturbance, n(%)	23 (95.8%)	13 (81.3%)	0.28
Duration of gait dysfunction(months), median (IQR)	24 (12-36)	24 (12-36)	0.93
Duration of cognitive dysfunction (months), median (IQR)	19.5 (8-24)	24 (6-48)	0.44
Duration of urinary disturbance (months), median (IQR)	18 (8-30)	18 (9-36)	0.97
Duration of falls (months), median (IQR)	7 (4-36)	12 (6-24)	0.63
iNPH gait score, median (IQR)	1 (1-2.5)	1 (1-2.5)	0.35
iNPH cognition score, median (IQR)	1 (1-2.5)	1 (1-2.5)	0.36
iNPH urinary score, median (IQR)	1.5 (1-3)	1 (1-2.5)	0.11
iNPH composite Score, median (IQR)	5 (3-7)	3 (2.5-5.5)	0.18
MoCA Score, mean±SD	17.4±6.1	15.2± 7.0	0.48
Modified Rankin Score (mRS), median (IQR)	3.0 (2.0–3.0)	3.0 (2.0–4.0)	0.48
mRS 1, n(%)	0	1 (6.2%)	0.54
mRS 2, n(%)	6 (37.5%)	6 (25%)	
mRS 3 , n(%)	10 (41.7%)	6 (37.5%)	
mRS 4, n(%)	7 (29.2%)	2 (12.5%)	
mRS 5, n(%)	1 (4.2%)	1 (6.3%)	
Timed Up and Go (TUG) (sec), mean± SD	30.6±11.2	28.2±13.6	0.67
Parkinsonism, n(%)	11 (45.8%)	6 (37.5%)	0.74
Lower body Parkinsonism, n(%)	4 (17.3%)	3 (20%)	>0.99
Falls, n(%)	11 (45.8%)	4 (25%)	0.32
Levodopa responsiveness ,n(%) (n=4)	1 (25%)	1 (25%)	>0.99

We also examined various gait scores and components of gait, as well as urinary and cognitive scales, at baseline and following the CSF-TT. We found no significant difference between the operated and non-operated groups. (Supplementary Table 2) We also found no difference between the operated and non-operated groups in terms of changes in Boon's gait score or its components, including total walk score, step score, time score, iNPH composite score, MoCA score, TUG test score, and mRS following the CSF-TT. (Table 2)

Table 2: Changes in gait parameters, iNPH score 24 hours after CSF tap test.

	Operated (n=24)	Non-operated (n=16)	P value
Walking Independently prior to CSF-TT, n/N(%)	18/24 (75%)	13/16 (81.3%)	0.72
Improvement in tandem walking, n/N(%)	3/18 (16.7%)	0	0.24
Improvement in turning, n/N(%)	9/18 (50%)	3/13 (23.1%)	0.16
Improved Trunk Balance, n/N(%)	2/18 (11.1%)	1/13 (7.7%)	>0.99
Improvement in Wide-Based Stride, n/N(%)	5/18 (27.8%)	2/13 (15.4%)	0.67
Improvement in Small Steps, n/N(%)	8/18 (44.4%)	4/13 (30.8%)	0.48
Improved Foot Clearance, n/N(%)	7/18 (38.9%)	4/13 (30.8%)	0.72
Improved Start Hesitation, n/N(%)	6/18 (33.3%)	1/13 (7.7%)	0.19
Resolved Tendency to Fall, n/N(%)	2/18 (11.1%)	2/13 (15.4%)	>0.99
Able to walk unassisted from pre-tap assisted walking/inability to walk, n/N(%)	2/6 (33.3%)	1/3 (33.3%)	>0.99
Total walk score change, median (IQR)	2 (0-6)	2 (0-3)	0.19
Steps score change, median (IQR)	2 (0-3)	0 (0-2)	0.06
Time score change, median (IQR)	1(0-2)	1 (0-3)	0.79
Gait Scale Total Score change, median (IQR)	5 (2-11)	3 (0-7.5)	0.19
MoCA change, median(IQR)	3 (1-5)	3.5 (1-5)	0.89
TUG change, median(IQR)	8 (2-11)	2.5 (0-5)	0.11
iNPH Composite Score change, median (IQR)	1 (0-1)	0.5 (0-1)	0.54
Modified Rankin Score change, median (IQR)	0 (0-1)	0 (0-1)	0.86

At 24 weeks follow-up (Table 3), a significant difference was observed between the operated and non-operated groups, with more patients in the operated group showing improvement in functional outcomes at 24 weeks compared to baseline. Fifteen patients showed an improvement of at least one

point in mRS (seven patients with a one-point improvement and eight patients with a two-point improvement), and four patients did not worsen further until 24 weeks. However, among non-operated patients, seven (42.8%) worsened at 24 weeks, one patient died before 24 weeks, and five (35.7%) remained unchanged. Two patients in the non-operated group who had improved mRS after the CSF tap test maintained the same mRS level until the 24-week follow-up.

Table 3: Comparison of mRS change at 24 weeks compared to baseline

	Post CSF tap test			**24 weeks of follow-up**		
	Operated (n=24)	Non-operated (n=16)	P value	Operated (n=24)	Non-operated (n=14)	P value
≥1-point worsening	0	0	>0.99	2(8.3%)	6(42.9%)	0.02
No change in MRS	13 (54.2%)	9 (56.3%)		4 (16.7%)	5 (35.7%)	
1-point improvement	9 (37.5%)	6 (37.5%)		7 (29.2%)	2 (14.3%)	
2-point improvement	2 (8.3%)	1 (6.3%)		8 (33.3%)	0	
Died	0	0		3 (12.5%)	1(7.1%)	

At baseline, both groups predominantly fell in the mRS 3–6 range, with no statistically significant difference between them. Following the CSF tap test, a shift toward better functional status (mRS 1–2) was observed in both groups; however, the improvement was not statistically significant. At 24 weeks, the operated group demonstrated a significantly higher proportion of patients in the mRS 1–2 category compared to the non-operated group (62.5% vs. 21.4%), indicating a favorable shift in short-term functional outcome following shunt surgery. (Figure 2)



Figure 2: Shift analysis showing comparison of patients' functional status at 24 weeks

Discussion:

In a highly selected cohort of patients with probable iNPH, our studies found that 62.5 % of patients responded to shunt surgery at 24 weeks with no significant difference in duration to shunt after CSF-TT between the shunt responders and non-responders. On the other hand, 16.7% were static, while 20.8% worsened despite surgery. Studies have shown that the outcome after surgery ranges from 38% to 81%.[1] In our study, a significant difference was observed in mRS change at 24 weeks between operated and non-operated patients, indicating improvement after shunt surgery. This is an interesting finding, given that there were no differences in response to large-volume CSF-TT between those who underwent surgery and those who did not. This finding aligns with the Japanese nationwide survey, which showed a significant improvement in the modified Rankin scale among shunt-operated patients compared to the non-operated group, regardless of the results of the CSF-TT.[8] SINPHONI study shows 80% of shunted patients respond in terms of improvement in mRS and 89% in terms of improvement in iNPH score.[9] Although surgery based on clinico-radiologic findings resulted in a response rate of 62.5% when using mRS as the outcome and 70% when using iNPH score as the outcome, our data did not identify a specific CSF tap test parameter to help predict patient prognosis for surgery. Our data did not reveal any significant differences in major parameters between the operated and non-operated patients, as assessed by Boon's gait scale, TUG test, and iNPH scale. However, our study showed that shunt responders were significantly older compared to shunt non-responders.[7] Also, the MoCA score at baseline was similar between the groups. This emphasizes the fact that the CSF tap test, which is considered to mimic VP shunting surgery, did not differentiate patients who will improve after shunt surgery. So, the diagnosis of definite iNPH before the actual VP shunt surgery is still a challenge. Existing literature highlights the poor negative predictive value of the CSF tap test. In our recent meta-analysis, the pooled sensitivity of the CSF-TT was 66.5% (95% CI: 49.6-81.6), and the pooled specificity was 52% (95%CI: 35.7-68.1).[10] This emphasizes that a negative tap test does not necessarily rule out shunt benefit. In our study, seven patients (46.7%) in the operated group who did not respond to the CSF tap test at 24 hours have responded to shunting. This suggests that a non-improved or borderline tap test response should not be excluded automatically from surgery if the clinical picture and imaging are strongly suggestive of iNPH.

Our study has several limitations. As a tertiary care institute, we often suffer from referral bias. It is possible that patients who had probable iNPH, but did not want to undergo CSF-TT or those who did not consider surgery following referral, were excluded from the cohort, as they did not present to our clinics. Although the decision to refer patients for surgery was not solely based on the CSF TT, all patients underwent the test. Consequently, those who did not undergo the CSF-TT were not referred for shunting, which led to selection bias by excluding individuals who declined consent prior to the tap test. The decision to operate was not randomized, and the reasons for no operations were variable, so selection bias is a possibility. Although we are a large-volume center, the sample size is small, which might affect the generalizability of our results. Thirdly, only functional improvement in mRS was focused on during outcome assessment. Improvement in other cognitive parameters and urinary disturbances at follow-up is unknown. The ambispective design might have introduced recall bias as the 24-week follow-up was based on self-reported recall. Few patients were followed up telephonically, and this could have

led to heterogeneity in outcome assessment. The patients were not blinded to the intervention, which could have introduced bias in the outcome reporting. The outcomes assessed were functional outcomes, which may not have been sensitive to minor improvements, particularly given the presence of older individuals with multiple comorbidities and orthopedic issues, potentially leading to an underestimation of the effects of shunt surgery.

Additionally, patients' shunt valve pressure adjustments and the timing of these adjustments were not recorded, which may have influenced the outcome assessment. Timely valve pressure programming may lead to appropriate drainage and improvement in symptoms. We reported the short-term functional outcomes at 24 weeks, and several studies have shown deterioration in the long term, thereby missing out the degenerative component of the disease.

Conclusion

Shunt surgery can be beneficial in a carefully selected subset of patients with idiopathic Normal Pressure Hydrocephalus (iNPH) who demonstrate a strong clinico-radiological profile. Many patients show a good clinical response in the short term following ventriculoperitoneal (VP) shunting. However, the cerebrospinal fluid (CSF) tap test alone lacks sufficient discriminatory power to accurately predict shunt responsiveness. It may therefore be inappropriate to exclude patients from shunt surgery solely based on a negative CSF tap test. Conversely, it should also be remembered that some patients with a positive CSF tap test do not go on to improve after surgery, highlighting the limitations of relying on this test alone. Moreover, currently available assessment techniques cannot reliably rule out the possibility of significant benefit after shunt placement. A comprehensive, multimodal approach—including detailed gait analysis, neuroimaging findings, and judicious use of the CSF tap test—is essential for selecting appropriate surgical candidates. Long-term outcomes following shunt surgery remain poorly understood and need to be systematically studied to inform prognosis and counsel patients.

Funding sources and conflict of interest: No specific funding was received for this work. The authors declare that there are no conflicts of interest relevant to this work.

Financial Disclosures for the previous 12 months: The authors declare that there are no additional disclosures to report.

Ethical Compliance Statement: The study was reviewed and approved by the Institute Ethics Committee at the All India Institute of Medical Sciences, New Delhi (No. IECPG-222/20.4.23, RT-14/07.06.23). Informed consent to participate in this study was provided by the participants and their legal guardians. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

References

1. Nakajima M, Yamada S, Miyajima M, et al. Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus. *Neurol Med Chir (Tokyo)*. 2021;61(2):63-97. doi:10.2176/nmc.st.2020-0292

2. Hu T, Lee Y. Idiopathic normal-pressure hydrocephalus. *Can Med Assoc J*. 2019;191(1):E15-E15. doi:10.1503/cmaj.180877

3. Carswell C. Idiopathic normal pressure hydrocephalus: historical context and a contemporary guide. *Pract Neurol*. 2023;23(1):15-22. doi:10.1136/pn-2021-003291

4. Elavarasi A, Poudel S, Dash D, et al. Current Practice Patterns Among Indian Neurologists in the Evaluation and Management of Normal Pressure Hydrocephalus: A Nationwide Cross-Sectional Survey. *SSRN*. Preprint posted online 2025. doi:10.2139/ssrn.5376438

5. Kazui H, Miyajima M, Mori E, Ishikawa M. Lumboperitoneal shunt surgery for idiopathic normal pressure hydrocephalus (SINPHONI-2): an open-label randomised trial. *Lancet Neurol*. 2015;14(6):585-594. doi:10.1016/S1474-4422(15)00046-0

6. Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PMcL. Diagnosing Idiopathic Normal-pressure Hydrocephalus. *Neurosurgery*. 2005;57(suppl_3):S2-4-S2-16. doi:10.1227/01.NEU.0000168185.29659.C5

7. Poudel S, Dash D, Fasano A, et al. Diagnostic Accuracy of CSF Tap-Test Parameters in Predicting Shunt Responsiveness in Normal Pressure Hydrocephalus: A Cohort Study. *SSRN*. Preprint posted online 2025. doi:10.2139/ssrn.5413559

8. Nakajima M, Miyajima M, Ogino I, et al. Shunt Intervention for Possible Idiopathic Normal Pressure Hydrocephalus Improves Patient Outcomes: A Nationwide Hospital-Based Survey in Japan. *Front Neurol*. 2018;9:421. doi:10.3389/fneur.2018.00421

9. Ishikawa M, Hashimoto M, Mori E, Kuwana N, Kazui H. The value of the cerebrospinal fluid tap test for predicting shunt effectiveness in idiopathic normal pressure hydrocephalus. *Fluids Barriers CNS*. 2012;9(1):1. doi:10.1186/2045-8118-9-1

10. Aliyar A, Dash D, Fasano A, et al. Accuracy of CSF Tap Test and Lumbar Infusion Test in Predicting Shunt Response in Idiopathic Normal Pressure Hydrocephalus: A Systematic Review and Meta-Analysis. *SSRN*. Preprint posted online 2025. doi:10.2139/ssrn.5392870